243 related articles for article (PubMed ID: 21251178)
1. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.
Barrington P; Chien JY; Showalter HD; Schneck K; Cui S; Tibaldi F; Ellis B; Hardy TA
Diabetes Obes Metab; 2011 May; 13(5):426-33. PubMed ID: 21251178
[TBL] [Abstract][Full Text] [Related]
2. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects.
Barrington P; Chien JY; Tibaldi F; Showalter HD; Schneck K; Ellis B
Diabetes Obes Metab; 2011 May; 13(5):434-8. PubMed ID: 21251179
[TBL] [Abstract][Full Text] [Related]
3. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study.
Umpierrez GE; Blevins T; Rosenstock J; Cheng C; Anderson JH; Bastyr EJ;
Diabetes Obes Metab; 2011 May; 13(5):418-25. PubMed ID: 21251180
[TBL] [Abstract][Full Text] [Related]
4. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study.
Grunberger G; Chang A; Garcia Soria G; Botros FT; Bsharat R; Milicevic Z
Diabet Med; 2012 Oct; 29(10):1260-7. PubMed ID: 22804250
[TBL] [Abstract][Full Text] [Related]
5. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
Flint A; Kapitza C; Hindsberger C; Zdravkovic M
Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616
[TBL] [Abstract][Full Text] [Related]
6. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.
Malloy J; Capparelli E; Gottschalk M; Guan X; Kothare P; Fineman M
Clin Ther; 2009 Apr; 31(4):806-15. PubMed ID: 19446153
[TBL] [Abstract][Full Text] [Related]
9. Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes.
Ehlers MR; Klaff LJ; D'Alessio DA; Brazg R; Kay HD; Harley RE; Mathisen AL; Schneider R
Horm Metab Res; 2003 Oct; 35(10):611-6. PubMed ID: 14605997
[TBL] [Abstract][Full Text] [Related]
10. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
Hermansen K; Bækdal TA; Düring M; Pietraszek A; Mortensen LS; Jørgensen H; Flint A
Diabetes Obes Metab; 2013 Nov; 15(11):1040-8. PubMed ID: 23683069
[TBL] [Abstract][Full Text] [Related]
11. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
12. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
Herman GA; Bergman A; Yi B; Kipnes M;
Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
[TBL] [Abstract][Full Text] [Related]
13. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
Kim D; MacConell L; Zhuang D; Kothare PA; Trautmann M; Fineman M; Taylor K
Diabetes Care; 2007 Jun; 30(6):1487-93. PubMed ID: 17353504
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.
Agersø H; Jensen LB; Elbrønd B; Rolan P; Zdravkovic M
Diabetologia; 2002 Feb; 45(2):195-202. PubMed ID: 11935150
[TBL] [Abstract][Full Text] [Related]
15. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
Linnebjerg H; Kothare PA; Skrivanek Z; de la Peña A; Atkins M; Ernest CS; Trautmann ME
Diabet Med; 2006 Mar; 23(3):240-5. PubMed ID: 16492205
[TBL] [Abstract][Full Text] [Related]
16. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
Devineni D; Morrow L; Hompesch M; Skee D; Vandebosch A; Murphy J; Ways K; Schwartz S
Diabetes Obes Metab; 2012 Jun; 14(6):539-45. PubMed ID: 22226086
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6).
Pratley RE; Urosevic D; Boldrin M; Balena R;
Diabetes Obes Metab; 2013 Mar; 15(3):234-40. PubMed ID: 22958426
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes.
Kapitza C; Heise T; Birman P; Jallet K; Ramis J; Balena R
Diabet Med; 2009 Nov; 26(11):1156-64. PubMed ID: 19929995
[TBL] [Abstract][Full Text] [Related]
19. Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction.
Morrow L; Hompesch M; Guthrie H; Chang D; Chatterjee DJ
Diabetes Obes Metab; 2011 Jan; 13(1):75-80. PubMed ID: 21114606
[TBL] [Abstract][Full Text] [Related]
20. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.
Nauck MA; Hompesch M; Filipczak R; Le TD; Zdravkovic M; Gumprecht J;
Exp Clin Endocrinol Diabetes; 2006 Sep; 114(8):417-23. PubMed ID: 17039422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
